February 16, 2017
Drug combo safe for diffuse large B-cell lymphoma
Drugs targeting the P13K-mTOR pathway add benefit when combined with standard R-CHOP therapy. The drug everolimus can be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma, according to the results of a pilot study by Mayo Clinic researchers. The researchers published their study findings in the July 2016 issue of […]
Tags: cancer, clinical trials, Forefront, hematology, lymphoma, Mayo Clinic Cancer Center, non-Hodgkin lymphoma, Patrick Johnston